Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R, Cueto-Ureña C, Welch C, Feliu I, Macaya I, Vera L, Morales X, Michelina SV, Scaparone P, Lopez I, Darbo E, Erice O, Vallejo A, Moreno H, Goñi-Salaverri A, Lara-Astiaso D, Halberg N, Cortes-Dominguez I, Guruceaga E, Ambrogio C, Lecanda F, Vicent S. Entrialgo-Cadierno R, et al. Among authors: guruceaga e. Mol Cancer. 2023 Jun 16;22(1):97. doi: 10.1186/s12943-023-01795-x. Mol Cancer. 2023. PMID: 37328838 Free PMC article. No abstract available.
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.
Valencia K, Erice O, Kostyrko K, Hausmann S, Guruceaga E, Tathireddy A, Flores NM, Sayles LC, Lee AG, Fragoso R, Sun TQ, Vallejo A, Roman M, Entrialgo-Cadierno R, Migueliz I, Razquin N, Fortes P, Lecanda F, Lu J, Ponz-Sarvise M, Chen CZ, Mazur PK, Sweet-Cordero EA, Vicent S. Valencia K, et al. Among authors: guruceaga e. J Clin Invest. 2020 Apr 1;130(4):1879-1895. doi: 10.1172/JCI129012. J Clin Invest. 2020. PMID: 31874105 Free PMC article.
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S. Vallejo A, et al. Among authors: guruceaga e. J Hepatol. 2021 Aug;75(2):363-376. doi: 10.1016/j.jhep.2021.03.028. Epub 2021 Apr 20. J Hepatol. 2021. PMID: 33887357 Free article.
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth.
Erice O, Narayanan S, Feliu I, Entrialgo-Cadierno R, Malinova A, Vicentini C, Guruceaga E, Delfino P, Trajkovic-Arsic M, Moreno H, Valencia K, Blanco E, Macaya I, Öhlund D, Khatri P, Lecanda F, Scarpa A, Siveke JT, Corbo V, Ponz-Sarvise M, Vicent S. Erice O, et al. Among authors: guruceaga e. Clin Cancer Res. 2023 Mar 14;29(6):1137-1154. doi: 10.1158/1078-0432.CCR-22-0794. Clin Cancer Res. 2023. PMID: 36607777
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R, Cueto-Ureña C, Welch C, Feliu I, Macaya I, Vera L, Morales X, Michelina SV, Scaparone P, Lopez I, Darbo E, Erice O, Vallejo A, Moreno H, Goñi-Salaverri A, Lara-Astiaso D, Halberg N, Cortes-Dominguez I, Guruceaga E, Ambrogio C, Lecanda F, Vicent S. Entrialgo-Cadierno R, et al. Among authors: guruceaga e. Mol Cancer. 2023 May 20;22(1):86. doi: 10.1186/s12943-023-01788-w. Mol Cancer. 2023. PMID: 37210549 Free PMC article.
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. Macaya I, et al. Among authors: guruceaga e. Nat Commun. 2023 Oct 10;14(1):6332. doi: 10.1038/s41467-023-41828-z. Nat Commun. 2023. PMID: 37816716 Free PMC article.
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: guruceaga e. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets.
Cortazar AR, Torrano V, Martín-Martín N, Caro-Maldonado A, Camacho L, Hermanova I, Guruceaga E, Lorenzo-Martín LF, Caloto R, Gomis RR, Apaolaza I, Quesada V, Trka J, Gomez-Muñoz A, Vincent S, Bustelo XR, Planes FJ, Aransay AM, Carracedo A. Cortazar AR, et al. Among authors: guruceaga e. Cancer Res. 2018 Nov 1;78(21):6320-6328. doi: 10.1158/0008-5472.CAN-18-1669. Epub 2018 Sep 19. Cancer Res. 2018. PMID: 30232219
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Vicente C, Arriazu E, Martínez-Balsalobre E, Peris I, Marcotegui N, García-Ramírez P, Pippa R, Rabal O, Oyarzábal J, Guruceaga E, Prósper F, Mateos MC, Cayuela ML, Odero MD. Vicente C, et al. Among authors: guruceaga e. Cancer Lett. 2020 Jan 1;468:1-13. doi: 10.1016/j.canlet.2019.10.007. Epub 2019 Oct 5. Cancer Lett. 2020. PMID: 31593801
85 results